保险类型与头颈癌诊疗时间进程的关联
这项回顾性队列研究比较了HMO、PPO和Medicare的头颈鳞癌患者在诊疗时间上的差异,发现HMO患者从主诉到活检、活检到专科医生门诊、手术到辅助放疗开始的时间间隔均显著延长,且术后6周内开始辅助放疗的比例更低。
要点
- HMO患者从主诉到活检、活检到专科门诊、手术到放疗开始的时间均显著长于Medicare和PPO患者。
- 术后6周内开始辅助放疗的比例:HMO 22%,Medicare 48%,PPO 61%。
- 保险类型可能影响头颈癌诊疗及时性,需进一步研究其是否为独立危险因素。
核心结论
- 与PPO和Medicare患者相比,HMO患者术后开始辅助放疗更晚,且在提供者类型转换和转诊专科医生过程中经历治疗延迟。
研究设计与样本
- 回顾性队列研究,纳入经活检证实为头颈鳞状细胞癌并转诊至学术三级中心行肿瘤切除和辅助治疗的患者,包括HMO(n=32)、Medicare(n=31)和PPO(n=41)患者。
主要发现
- HMO患者从主诉到活检(P = .003)、活检到首次专科外科医生门诊预约(P < .001)、手术到辅助放疗开始(P < .001)的时间间隔均显著长于Medicare和PPO患者。
- 术后6周内开始辅助放疗的患者比例:HMO 22%(平均59 ± 17天),Medicare 48%(44 ± 13天),PPO 61%(41 ± 12天)。
临床怎么用
- 临床应关注HMO头颈鳞癌患者在诊疗过渡和转诊过程中的延迟风险,尤其术后辅助放疗的及时启动。
局限性
- 研究为回顾性设计,证据等级为4级,样本量有限,需进一步研究验证保险类型是否为延迟就诊的独立危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To determine differences in time course of care based on major insurance types for patients with head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Retrospective cohort study. METHODS: Retrospective study of Health Maintenance Organization (HMO), Preferred Provider Organization (PPO), and Medicare patients with biopsy-proven diagnosis of HNSCC referred to an academic tertiary center for tumor resection and adjuvant therapy. In addition to patient demographic information and tumor characteristics, duration of chief complaint and the following time points were collected: biopsy by referring physician, first specialty surgeon clinic appointment, surgery, and adjuvant radiation start and stop dates. RESULTS: There was a statistically significant increase in time interval for HMO (n = 32) patients from chief complaint to biopsy (P = .003), biopsy to first specialty surgeon clinic appointment (P < .001), and surgery to start of adjuvant radiation (P < .001) compared to that of Medicare (n = 31) and PPO (n = 41) patients. Adjuvant radiation was initiated ≤6 weeks after surgery in 22% of HMO (mean duration of 59 ± 17 days), 48% of Medicare (44 ± 13 days), and 61% of PPO (41 ± 12 days) patients. CONCLUSIONS: Compared to PPO and Medicare patients, HMO patients begin adjuvant radiation after surgery later and experience treatment delays in transitions of care between provider types and with referrals to specialists. Delaying radiation after 6 weeks of surgery is a known prognostic factor, with insurance type playing a possible role. Further investigation is required to identify insurance type as an independent risk factor of delayed access to care for HNSCC. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:E587-E592, 2020.
引用
- Itamura K, Kokot N, Sinha U, et al. Association of insurance type with time course of care in head and neck cancer management. Laryngoscope. 2019. PMID: 31756005. doi:10.1002/lary.28423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。